0001090872-25-000036
SEC filingAgilent reported 10% revenue growth in Q3 FY25, driven by Life Sciences and Diagnostics Markets, but gross margin declined 310 bps due to tariffs and mix.
For the three months ended July 31, 2025, Agilent reported net revenue of $1,738 million, a 10% increase year-over-year. Foreign currency movements had a 2 percentage point favorable impact. Gross margin contracted 310 basis points to 51.1% from 54.2% in the prior year, primarily due to higher tariffs, increased shipping costs, unfavorable product mix, and higher wages and variable pay, partially offset by higher sales volume and lower warranty and restructuring expenses. Operating income rose 8% to $360 million, with operating margin declining 40 basis points to 20.7% as revenue growth was offset by cost pressures. Net income increased 19% to $336 million, benefiting from a $28 million tax benefit from the release of tax reserves.
Life Sciences and Diagnostics Markets segment revenue grew 14% to $670 million, with organic growth of 10% (BIOVECTRA contributed 4 percentage points). The segment's gross margin fell 390 basis points to 50.5% due to tariffs and unfavorable mix. Operating margin declined 200 basis points to 17.6%, yet operating income rose 3% to $118 million. Growth was led by strong demand in the pharmaceutical market (CDMO, LC/LCMS) and diagnostics/clinical market (companion diagnostics, pathology). Agilent CrossLab revenue increased 8% to $744 million, with a 300 basis point favorable currency impact. Gross margin dropped 260 basis points to 55.1% due to tariffs and higher costs, while operating margin contracted 260 basis points to 33.3%. Operating income was flat at $248 million as higher costs offset revenue growth. Growth was broad-based across services and consumables. Applied Markets revenue rose 7% to $324 million, with a 200 basis point FX tailwind. Gross margin declined 160 basis points to 53.6% due to tariffs and variable pay, and operating margin slipped 140 basis points to 21.8%. Operating income increased 1% to $71 million. Growth was driven by chemicals, pharmaceuticals, and food markets, offset by weakness in environmental/forensics and academic/government.
Management's outlook indicates cautious optimism with signs of steady market recovery. The company expects to substantially mitigate the impact of recent tariff changes by fiscal year 2026 through supply chain optimization, targeted pricing actions, and cost-efficiency initiatives. Key strategic priorities include enhancing customer experience, delivering differentiated product solutions, and driving productivity improvements. The company continues to invest in expanding its applications and solutions portfolio, particularly in CDMO for nucleic acid therapeutics, and expects capital expenditures of approximately $400 million for fiscal 2025. No specific numerical guidance was provided for the upcoming periods.
As of July 31, 2025, Agilent held $1.535 billion in cash and cash equivalents, with total debt of $3.409 billion ($59 million short-term, $3.350 billion long-term). Shareholders' equity stood at $6.370 billion. Inventory increased to $1.014 billion from $972 million at October 31, 2024. Deferred revenue (contract liabilities) rose to $800 million from $701 million at the start of the fiscal year, reflecting growth in advance payments from customers. The company's $1.5 billion revolving credit facility and $300 million uncommitted money market line remained undrawn as of July 31, 2025.
The Notes disclose no specific purchase commitments or contractual obligations beyond standard warranty accruals ($28 million) and bank guarantees ($40 million). The company has two interest-free loans from the Strategic Innovation Fund and Atlantic Canada Opportunities Agency related to the BIOVECTRA acquisition, with current portion of $4 million and non-current portion of $21 million as of July 31, 2025. Remaining performance obligations for contracts with original terms exceeding one year totaled $425 million, the majority expected to be recognized within 12 months.
During the nine months ended July 31, 2025, Agilent repurchased 2.734 million shares for $340 million (excluding excise taxes of $2 million), leaving $34 million remaining under the 2023 repurchase program. A new $2.0 billion authorization was approved on May 29, 2024, effective August 1, 2024. Dividends totaled $212 million ($0.744 per share), up from $206 million ($0.708 per share) in the prior-year period. Capital expenditures were $314 million (6.2% of revenue). Net debt increased by $19 million, with $1.118 billion in commercial paper borrowings and $1.103 billion in repayments.
For the nine months ended July 31, 2025, segment revenue: Life Sciences and Diagnostics Markets $1.971 billion (+9.0% YoY), Agilent CrossLab $2.153 billion (+5.5% YoY), Applied Markets $963 million (+0.4% YoY). Segment operating income: Life Sciences and Diagnostics Markets $364 million (18.5% margin), Agilent CrossLab $700 million (32.5% margin), Applied Markets $214 million (22.2% margin). Geographically, Americas contributed $2.030 billion, Europe $1.397 billion, and Asia Pacific $1.660 billion. Revenue by end market: Pharmaceutical and Biopharmaceutical $1.817 billion, Diagnostics and Clinical $753 million, Academic and Government $404 million, Chemicals and Advanced Materials $1.147 billion, Food $472 million, Environmental and Forensics $494 million.
Operating cash flow (CFO) of $1.014B exceeded net income of $0.869B, indicating healthy cash conversion despite a 20% year-over-year decline. The primary driver of the CFO decrease was a significant working capital outflow of $0.216B (accounts receivable, inventory, and other assets/liabilities) versus an inflow of $0.12B in the prior period, reflecting slower collections and inventory build.
Capital expenditures increased by 10% to $0.314B, representing a 31% capex intensity relative to CFO, up from 22% last year. Free cash flow (CFO minus capex) was approximately $0.700B, though not explicitly stated in the filing.
Capital returns to shareholders totaled $0.552B, composed of $0.34B in share repurchases and $0.212B in dividends. This was comfortably covered by CFO, with a payout ratio of 54%. The company also repurchased additional shares and paid excise taxes, indicating a balanced approach to capital allocation amid reduced operating cash generation.
Notable anomalies include a $0.304B income tax payment (net of refunds), which is high relative to net income and may reflect prior-year settlements. Also, the net gain on equity securities and asset impairment charges added non-cash adjustments totaling $0.043B. Overall, cash flow quality remains adequate but is pressured by working capital outflows and rising capex.